Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $0.74, but opened at $0.78. Adamis Pharmaceuticals shares last traded at $0.90, with a volume of 3,263,900 shares traded.

A number of equities analysts have weighed in on ADMP shares. Dawson James assumed coverage on Adamis Pharmaceuticals in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Maxim Group set a $6.00 target price on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 9th. ValuEngine lowered Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. B. Riley raised shares of Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research report on Tuesday, July 23rd. Finally, Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $3.87.

The firm’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.65. The firm has a market cap of $48.20 million, a PE ratio of -0.90 and a beta of 1.33. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.79 and a current ratio of 1.04.

Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%. The firm had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $5.82 million. On average, analysts forecast that Adamis Pharmaceuticals Corp will post -0.46 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. National Asset Management Inc. increased its stake in Adamis Pharmaceuticals by 28.9% during the first quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock worth $64,000 after acquiring an additional 6,710 shares during the last quarter. Wedbush Securities Inc. lifted its stake in shares of Adamis Pharmaceuticals by 139.8% in the 2nd quarter. Wedbush Securities Inc. now owns 44,600 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 26,000 shares during the last quarter. A.R.T. Advisors LLC grew its holdings in shares of Adamis Pharmaceuticals by 143.8% during the 2nd quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock worth $80,000 after purchasing an additional 36,400 shares during the period. Leisure Capital Management grew its holdings in shares of Adamis Pharmaceuticals by 4.5% during the 1st quarter. Leisure Capital Management now owns 115,724 shares of the specialty pharmaceutical company’s stock worth $244,000 after purchasing an additional 4,967 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Adamis Pharmaceuticals during the 2nd quarter worth $181,000. Institutional investors own 12.11% of the company’s stock.

Adamis Pharmaceuticals Company Profile (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Further Reading: Portfolio Manager

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.